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Through wide-spanning policy changes, disparities in access to transplantation and 
transplantation rates have been created, in both the past and current liver and kidney transplant 
allocation systems. These disparities mainly affect women and minorities, and can be lessened, 
and in some ways eliminated, through concentrated efforts by policy makers and public health 
officials. The current waitlist burdens, allocation policies and transplantation rates, are described 
in this essay with the purpose of identifying weak areas in the current system where policy 
amendments and public health interventions would be most beneficial. Proposed changes to the 
current allocation policy in liver and kidney transplantation include the redrawing of borders in 
which organs are shared and altering the MELD score for women to better reflect smaller physical 
traits of women, in the liver allocation system, and expanding the role of kidney paired donation 
in renal transplantation. In conjunction with policy changes, interventions that increase education 
and awareness of the need for living donor organs and the importance of decreasing Hepatitis C 
transmission can be directed to problematic communities. While the solutions for observed 
disparities in both liver and kidney transplantation may not be obvious, understanding the 
epidemiologic factors that lead to observed disparities in organ allocation systems for liver and 
kidney transplantation are of paramount public health importance because they have the potential 
to limit millions of people from obtaining a life-saving therapy. 
Tina Costacou, PhD 
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1.0 INTRODUCTION 
1.1 END-STAGE RENAL DISEASE 
The kidneys are two bean-shaped organs located on either side of the spine behind the 
upper abdominal organs and play a critical role to normal physiology. Using tiny structures called 
nephrons and glomeruli, they kidneys filter the blood of waste products that can become toxic if 
allowed to accumulate; remove excess fluid around the heart and the lungs; return nutrients to the 
blood stream; and help regulate blood pressure and prevent anemia. Most kidney diseases assault 
the nephrons. Chronic kidney disease (CKD) gradually damages the nephrons over several years. 
It is characterized by declining kidney function, assessed by the glomerular filtration rate (GFR) 
of kidneys, and is divided into five stages of increasing severity.[1]  In normal functioning kidneys, 
GFR exceeds 90 mL/minute/1.73m3. As GFR decreases, the severity of CKD increases by 
increasing stages of disease.[1] End-stage renal disease (ESRD) develops when the kidneys fail to 
function at the level required for normal physiology, i.e. when the GFR falls below 15 
mL/minute/1.73m3.[1] ESRD poses significant burden to the society. It accounts for 4.9 deaths per 
100,000 in the United States and it is the ninth leading cause of death.[2] 
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The main causes of ESRD are diabetes and high blood pressure.[1, 3, 4] People at increased 
risk of developing ESRD include those with a family history of kidney disease, history of 
hypertension or diabetes, and persons that belong to populations that are more likely to have the 
former risk factors (i.e. Blacks, Hispanics, Asians, and Native Americans).[1] 
Prevalence and incidence of CKD/ESRD in the United States 
Currently, 26 million adults are estimated to have CKD in the United States.[1] In adults 
over the age of 30 years, the estimated burden of CKD is 13.2% and is expected to increase to 
14.4% by 2020 and to 16.7% by 2030.[5] For age groups 30-49, 50-64 and ≥65, the lifetime 
incidence of CKD is 54.13%, 52.01% and 41.8%, respectively. The incidence of end stage renal 
disease is much lower for these groups and is estimated to be 3.17% for the 30-49 age group, 
3.31% for the 50-64 age group, and 2.63% for adults over the age of 65 years. The most common 
stage of disease is Stage 3 of CKD where the GFR is functioning at 30-59 mL/minute/1.73m3.[5] 
Racial/ethnic differences exist in CKD. Thus, although the prevalence of CKD in adults 
older than 30 years and in those >65 is similar between blacks and non-blacks (estimated at 13.2% 
and ~40%, respectively), blacks have a higher prevalence among 30-49 year olds (5.6% versus 
3.8%) and in the 50-64 age group (13.62% versus 9.42%).[5] The lifetime incidence of ESRD is 
also higher in blacks compared to non-blacks in the 30-49 age group (6.56% vs. 2.73%), the 50-
64 age group (8.45% vs. 2.72%) as well as in adults over 65 years (7.22% vs. 2.22%).[5] 
Risk factors for ESRD
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ESRD prevention in early stages of CKD includes limiting salt intake to prevent 
hypertension and decreasing the risk of diabetes through balanced dieting and exercise. In addition, 
avoiding the overuse of non-prescription pain relievers and limiting the intake of alcoholic drinks 
are steps to ensuring a healthier lifestyle and preventing chronic kidney disease from occurring.[1] 
Once ESRD has occurred, however, dialysis, an artificial means of filtering the blood, is required 
for these patients. There are two types of dialysis: hemodialysis, in which an artificial kidney is 
used to filter the blood, and peritoneal dialysis, in which a special cleaning solution (dialysate) 
passes into the abdomen via a catheter to filter the blood.[6] A disadvantage of kidney dialysis is 
that it involves strict scheduling and lifestyle modifications which may interfere with the patient’s 
ability to work and/or continue with other daily activities. An alternative treatment option of 
replacing kidney function is by kidney transplantation. 
1.2 END STAGE LIVER DISEASE 
The liver is a large organ mainly located in the upper right quadrant of the abdomen. The 
liver performs a multitude of critical functions relating to digestion, metabolism (including of 
drugs), detoxification, immunity and the storage of energy. Chronic liver disease (CLD) involves 
the progressive destruction of liver tissue over time. It is a term that is applied to various clinical 
disorders that cause the liver to fail to perform its functions and it can vary from mild liver test 
abnormalities to end stage liver disease (ESLD), which is the most severe form of liver disease. 
Cirrhosis is an irreversible, life-threatening condition in which liver tissue is replaced by scar, non-
functioning, tissue.[7] A decrease in liver function usually occurs when more than 75% of liver 
tissue is affected by disease and 80-90% of liver tissue needs to be destroyed before any clinical 
Treatment options for ESRD
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signs of liver failure.[8] Unlike chronic kidney disease, there is no definitive event such as the drop 
in GFR for ESRD, that occurs in chronic liver disease to signify that a patient has CLD; therefore, 
assessing the prognosis of liver disease is extremely difficult from patient to patient. 
Causes and risk factors for ESLD 
An extensive list of conditions is associated with CLD. The most common cause of liver 
disease in the United States is alcohol abuse.[7] Other common causes of CLD include viruses 
(e.g. hepatitis B and C, cytomegalovirus, and Epstein Barr virus), genetic predispositions, 
disorders of the immune system (e.g. autoimmune hepatitis), reactions to medications or toxins, 
and unhealthy lifestyle choices relating to illicit drug use and risky sexual behaviors, where 
hepatitis C (HCV) can be transmitted. Severe scarring of the liver, or cirrhosis, can result from 
these causes and cirrhosis can lead to liver cancer or hepatocellular carcinoma (HCC).[7] Cirrhosis 
does not present equally in every patient and does not always lead to carcinoma, which makes 
diagnosis of ESLD and subsequent estimation of burden of ESLD very challenging. Other 
consequences of as a result of liver disease are premature death, esophageal bleeding, liver 
transplantation and liver cancer.[7] 
The populations at the highest risk of CLD are minorities, the poor, uninsured, former or 
current drug users and alcoholics. The primary cause of end stage liver disease is hepatitis C 
infections (HCV) followed by malignancies that could potentially overlap with HCV.[7] 
Prevention of chronic liver disease includes a balanced diet, abstaining from illegal drug use and 
the sharing of needles, safe sexual practices, and drinking alcohol in moderation.[7] 
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The burden of liver disease is difficult to estimate because CLD encompasses many 
disorders of the liver without one specific, defining event being able to accurately and consistently 
predict that a patient is undergoing liver damage.[7] Nevertheless, in a recent report using data 
from the National Health and Nutrition Examination Survey (NHANES) conducted between 1999 
and 2010, the prevalence of cirrhosis was estimated to approximate 0.27%, a higher proportion 
than previously anticipated.[9] This proportion would correspond to 633,323 adults in the United 
States being afflicted with cirrhosis of the liver based on 2010 US census data. Study investigators 
noted a bimodal age distribution in cirrhosis prevalence, with peaks during the fourth and fifth 
decade as well as after 75 years.[9] In multivariable logistic regression, men were greater than two 
times more likely to be affected by liver cirrhosis, as were individuals with a diabetes diagnosis. 
Blacks and Hispanics also had greater odds of liver cirrhosis although the results did not reach 
statistical significance. Alarmingly, 70% of these individuals reported being unaware of having 
liver disease. 
Treatment options for ESLD 
Although liver damage from cirrhosis is not reversible, depending on the cause and stage 
of liver cirrhosis, treatment could stop or delay further disease progression and prevent or minimize 
complications. Improvements in lifestyle factors such as diet and weight reduction, treatment of 
alcohol dependency, adherence to medication regimen for hepatitis control, may minimize liver 
damage in early stages of cirrhosis.[10] However, in cases of advanced liver disease, where the 
liver ceases to function, a liver transplant may be the only available treatment option. The chapters 
to follow will focus on this well-established form of treatment, the shortage of donor organs and 
unintended disparities in accessing this treatment option created by organ allocation systems. 
Prevalence of ESLD
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1.3 TRANSPLANTATION OVERVIEW 
Better surgical technique, perioperative care and major advancements in 
immunosuppression have transformed the field of transplantation from an experimental procedure 
to wide acceptance as an effective and life-saving method for treatment of ESRD and ESLD.[11-
14] While wide-spanning policy changes have been successful in increasing access to 
transplantation therapy and in improving allocation of organs,  unintended disparities in access to 
transplantation and transplantation rates have been created, in both the past and current liver and 
kidney transplant allocation systems. These disparities mainly affect women and minorities and 
could be lessened, and perhaps even eliminated, through concentrated efforts by policy makers 
and public health officials. The current waitlist burdens, allocation policies and transplantation 
rates, are described below with the purpose of identifying weak areas in the current system where 
policy amendments and public health interventions would be most beneficial. 
In 1984, with the passing of the National Organ Transplant Act (NOTA), the United States 
Congress established the Organ Procurement and Transplantation Network (OPTN) which was to 
be headed by a private, non-profit organization, the United Network for Organ Sharing (UNOS), 
with federal oversight by the Health Resources and Services Administration (HRSA) of the Health 
and Human Services Department (HHS). This act came in response to the nation’s erratic 
transplantation climate, caused both by a critical organ donation shortage; as well as problems in 
the matching and allocation processes. Both of these processes were plagued by “privileged 
access” by certain patient demographic groups, while transplant therapy remained hindered for 
many other patient populations.[15, 16] As part of this network, the United States was divided into 
11 regions, grouping several states, in order to create OPTN regions; these regions are further 
divided into Donor Service Areas (DSAs) that are defined as the areas from which Organ 
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Procurement Organizations (OPOs) collect and allocate organs to transplantation centers (Figure 
1). Since its beginnings, the goals of UNOS have been to balance utility and equity, in the 
allocation of deceased donor organs through efforts in the form of both broad and selective policy 
changes, in order to optimize allocation to meet these often competing goals. 
Figure 1. OPTN Regions [17] 
Wide spanning policies have been the primary vehicle for permanent change in the 
allocation system for all organs. Allocation policies in the liver have moved away from a wait time 
designation to addressing more urgent cases of ESLD based on a calculated score (Model for End-
Stage Liver Disease – MELD score) that predicts the three month survival of a particular patient 
if they would not receive a transplant. MELD score ranges from 6-40 with higher MELD scores 
indicating a higher chance of mortality due to ESLD.[12, 18] While the MELD score is an accurate 
predictor of survival, there exists no database of people diagnosed with ESLD that can verify the 
extent to which this measure is precise. Such a database exists within the United States Renal Data 
System for ESRD and it tracks all patients from the start of dialysis. 
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In renal transplantation, the snowball effect of “baby boomers” on the health care system 
has overwhelmed the waitlists and created an even more desperate need for organs.[19] Allocation 
systems that had been previously based on human leukocyte antigen (HLA) matching have 
transformed into allocation systems based on waiting time, and even more recently as of December 
2014, it has turned into an allocation system based on a refined metric (Kidney Donor Profile Index 
– KDPI) for assessing how long a kidney is expected to function post-transplantation.[18] With 
the exception of this new renal allocation system, policy changes in renal and liver transplantation 
are responsible for the most current reports regarding the transplantation rates in the US and the 
waitlist burdens for ESLD and ESRD patients. 
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1.4 WAITLIST BURDENS IN LIVER AND KIDNEY TRANSPLANTATION 
In liver transplantation, data from 2013, the most recent and fully-completed year, 
estimates the waitlist burden to be 15,027 candidates awaiting transplantation, including 12,407 
candidates in active status. Overall, in 2013, and there were 5,921 transplants performed and it was 
shown that 1,767 candidates died on the waitlist while 1,223 were removed from the list for being 
too sick to undergo transplant.[20, 21] The highest proportion of those waitlisted are aged 50-64 
(61.5%), white (70.7%) followed by Hispanics (16.9%), males (65.9% of all transplants), most 
candidates have MELD scores 15-29 at the time of transplant and hepatitis C infection is the 
leading cause of ESLD (29.3%). The majority of deaths prior to transplant occur in individuals 
older than 65 years.[20, 21] 
 Despite the increased and continuing need for transplantable organs, the number of living 
donor donations has decreased. A partial explanation for this decline is the observation of an 
increase in living donor readmissions to the hospital in the first year after transplantation. These 
readmissions are largely due to biliary and vascular complications. More studies in living donors 
need to be done in order to elucidate these findings and this should be done prior to the publication 
of the annual report for 2014. In contrast to the increased complication rates among living donors, 
outcomes for deceased donor recipients have continued to improve over the years. The highest 
survival rates are in recipients in the 35-49 age group and lowest in adults over the age of 65 
years.[20, 21]  
Renal transplantation mirrors the burdens of liver transplantation and over the past decade, 
little has changed in terms of total numbers of transplants. Yearly, the total number of candidates 
on the waiting list increases and in the most recent report for 2013, the waitlist for kidney 
transplantation was estimated to be over 97,000.[3, 4] The highest proportion of all transplants 
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occurred in candidates aged 50-64 with organs from both deceased donors and living donors.[3, 4] 
In addition, a greater proportion of renal transplants has been reported among males (51.8% of all 
transplants), whites (65.8% of all transplants), and the primary cause of ESRD has been reported 
to be diabetes (29.3%).[3, 4] Like in the liver, outcomes in kidney transplantation have improved 
tremendously with advances in immunosuppression.[11] However, graft failure and return to 
dialysis increases as the transplant recipient furthers away from the date of transplantation. Graft 
survival from living donors is higher than graft survival from deceased donors and overall survival 
is almost identical among by race, except for a sharp decline that has been observed in blacks 
within 60 months after transplantation.[3, 4] 
These current rates are the end result of numerous policy changes that have been put forth 
by UNOS in order to solve the issue of the growing waitlist and the shortage of organs. While 
allocation in the U.S. does help to transplant many individuals, epidemiologic factors such as race, 
age, gender, socioeconomic status and geographic variation create disparities in both liver and 
renal transplantation and hinder the current allocation systems from making organs available for 
the greatest number of people.  
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2.0  LIVER TRANSPLANTATION: HISTORICAL PERSPECTIVE AND CURRENT 
STATUS 
Prior to the introduction of the MELD score, there were unequal transplantation rates 
between minorities and whites, and between genders. Subjective criteria were used to prioritize 
and evaluate whether a patient was eligible for transplantation.[12] Early allocation was based on 
location (outpatient setting, hospital ward or intensive care units—ICUs) in order to account for 
the urgency in which transplantation was needed. This led to large groups of candidates, in ICUs 
for example, remaining poorly differentiated and it increased the discrepancies in transplantation 
rates among all patient demographics. Blacks had more advanced disease at the time of wait-listing 
and were more likely to die while waiting for a graft.[22, 23] At listing, blacks tended to be younger 
and presented with worse disease than whites.[22] There was a significant discrepancy in the 
transplantation rate between whites and blacks, with whites being more likely to obtain 
transplantation once waitlisted. Blacks remained on the waitlist for longer periods of time and 
underwent prolonged dialysis.[22, 24] Gender discrepancies existed prior to the MELD score as 
well, however, this disparity is still continuing today, albeit to a lesser extent.[22, 25, 26] Prior to 
the institution of the MELD score, women were more likely to die or become too sick to transplant 
within three years of being added to the waitlist and they were less likely than men to undergo 
transplant.[25, 26]  
In 2003, MELD score became the basis of the allocation system after efforts were set to 
ensure a fair distribution of organs in the system to those with the greatest need: the sickest patients. 
MELD is based on three laboratory tests: international normalized ratio (INR) of the prothrombin 
time, total serum bilirubin and serum creatinine.[18] It is a reliable clinical tool for consistent and 
 12 
accurate estimation of three month mortality for a wide range of chronic liver disease patients 
based on objective criteria.[12, 27-29] Under the MELD system, priority is given first to acute 
liver failure candidates who face the risk of mortality within hours or days of diagnosis. These 
patients are designated status 1A and livers are offered to them, first at the local level and then to 
status 1A candidates at the regional level. Next, status 1B patients who are very sick, chronically 
ill pediatric patients, are offered livers first at the local level and then at the regional level. 
Prioritization is then designated by MELD score ≥15, first locally then regionally. If the liver is 
not accepted by any of the above, the liver is then offered to MELD ≤15 candidates first at the 
local level then regionally. Lastly, the liver is offered sequentially to 1A, 1B and all others 
prioritized by MELD at the national level.[12, 18, 30] MELD scores ≥18 have been found to be 
significantly associated with benefit in transplantation therapy and studies have shown that 
increasing MELD scores are proportional to benefit of transplantation therapy.[31] MELD scores 
15-17 represented a transition point where there was much ambiguity about the benefit of 
transplantation and MELD scores lower than 15 had a higher benefit without transplantation. For 
candidates with MELD scores less than 15, the benefit was greater without transplantation because 
these patients still had longevity with their own grafts.[27, 31]  
The current allocation policy offers organs to those that gain the most benefit from 
transplantation or candidates with MELD ≥15 first at the local level then regionally to increase 
benefit of transplantation.[18] There is a large geographic component to this. Previously, organs 
were being offered in descending order of MELD scores within the same OPO leading to high 
rates of transplantation in MELD scores less than 18, which decreased the benefit of 
transplantation therapy in these individuals.[31]  In the older system, many OPOs were doing 
transplants in MELD scores lower than 15, where some were transplanting patients as low as 
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MELD 7.[32] The allocation policy has since been updated and as was previously stated, organs 
are offered by MELD score first locally then to candidates with the same MELD score at the 
regional level before this organ would be offered to a candidate with a lower MELD score.[18] In 
the current policy, scoring changes as the disease progresses and the score is updated during the 
course of ESLD treatment. Certain diseases are eligible for MELD score exceptions that award 
higher points to candidates. Hepatocellular carcinoma (HCC) patients are given a MELD exception 
and are automatically given higher scores (i.e. 20-22) in order to reach the top of the transplant list 
for transplantation to occur before the carcinoma is able to spread to the surrounding lymphatic 
system.  
The effectiveness of MELD scoring is invalidated by the diseases that are granted an 
exception to calculated MELD scoring, due to the fact that MELD scores are unable to accurately 
predict the urgency in which transplantation therapy is needed. In the example of HCC patients, 
urgency of the need for transplantation cannot be calculated before the cancer is able to spread. In 
the current system, additional MELD exception points are given to HCC patients with tumors 
meeting the Milan criteria of a single tumor no more than 5cm in diameter or fewer than three 
tumors each no more than 3cm in diameter in order to move these patients further up the 
waitlist.[18] HCC patients were initially and arbitrarily given MELD scores ranging from 24-29 
in order to help predict the urgency of the disease, however, in 2003, this was modified to MELD 
20-22.[12, 23, 27] Rates of transplant in HCC patients immediately rose and disparities were 
reduced across races and genders.[23, 33] Even though the assignment of MELD scores for HCC 
patients is arbitrary and represents a failure of the MELD system to predict urgency of disease, the 
reduced differences in transplant rates of patients diagnosed with HCC represents the efficiency 
of the MELD system to identify the sickest individuals.[23, 27, 34]  
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This new scoring system has also helped to diminish disparities in transplantation by race 
and gender. In the pre-MELD era, blacks were less likely to receive a liver transplant than white 
patients within three years of registering on the waiting list; whereas post-MELD, race was no 
longer significantly associated with receipt of a liver transplant. Blacks had a 20% increased risk 
of death in the pre-MELD era if listed without HCC and an equal risk in the post-MELD era 
compared with white men.[23] Likewise, women listed without HCC had a higher risk of dying or 
becoming too sick to transplant while on the waitlist in the pre-MELD era. However, after the 
implementation of the MELD score, men and women both had high rates of transplantation if listed 
with a diagnosis of HCC (72.2% vs 74.0%, respectively) although, women had a higher risk of 
death than men if listed without an HCC diagnosis.[23]   
Recently, however, there has been a slight decline in the overall number of livers 
transplanted in HCC patients. While it is still greater than the number of transplants, in this 
population, prior to the implementation of the MELD based allocation system, the rates of 
transplant were somewhat decreased between the years 2009-2010.[35] In one study by Halazun 
et al, it was found that transplantation rates varied greatly by region in the amount of time that 
HCC patients spent on the waitlist.[36] In regions where the waiting time was short, HCC patients 
had worse overall survival than HCC patients in regions where the wait time was longer. It was 
also found that being listed and transplanted in regions with short waiting time was an independent 
predictor of poor patient survival on multivariable analysis.[36] In addition to decreased rates in 
HCC patients, minorities were significantly less likely to undergo liver transplantation during this 
same time period.  
When comparing between DSAs among all 11 OPTN regions, there exists great variation 
in organ access, which leads to varying risk of death for a liver transplant candidate.[37] Ideally, 
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a candidate has the highest likelihood for transplantation in areas where the waitlist is short and 
the availability of organs is high. Geography-associated imbalance in organ availability is largely 
demand driven, and demand is proportional to increasing populations. In large metropolitan areas, 
demand is especially high and it is in these same areas that minority populations are large.[37] 
This recent decline in transplantation rates of  HCC patients does not indicate that the MELD 
system has failed to work in  the HCC population; rather, it directly shows the great need of organs 
for these very sick patients.[35]  
As it was briefly mentioned above, after the introduction of the MELD score, disparities in 
liver transplantation were decreased and, in some cases, eliminated. Once waitlisted, blacks had 
the same transplantation rates as whites despite having higher MELD scores at listing.[22-24] 
Blacks had a lower mortality than whites while on the waitlist, as well.[24, 38]  Shorter waiting 
times were observed for higher MELD scores.[12, 23, 24] Women were still less likely to undergo 
transplantation than men; however, this disparity was attenuated with the introduction of 
MELD.[23] Disparities within blood group ABO continued in the MELD era. In the donor pool, 
there are more blood type O donors than waitlisted recipients. Type-O candidates remain on the 
waitlist longer than others in both pre- and post-MELD eras.[39] Graft survival is higher in 
identical ABO matching and slightly lower when blood types are compatible. Type-O organs are 
disproportionately going to compatible recipients rather than blood type O recipients.[39]  
Aimed at increasing transplantations and further decreasing disparities, several policy 
changes have been put in place in order to improve components of the MELD system. Due to the 
arbitrarily drawn regional borders of the OPTN, many livers were transplanted locally into 
recipients with lower MELD scores even when candidates with higher MELD scores were still on 
the waitlist in neighboring OPTN regions and its DSAs. In 2005, Share 15 policy was implemented 
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in order to improve organ allocation for local and regional candidates with MELD scores ≥15. If 
an organ became available at the local level and it did not match any candidates with MELD ≥15, 
the policy allows for the organ to be offered at the regional level for any potential matching 
candidate with MELD ≥15. [40] Outcomes of this policy were positive: there was a drop of 26% 
of livers being offered to candidates with MELD <15, where the benefit of transplantation was 
low, and there was a reduction in variability of MELD scores at the time of transplantation across 
the country.  
There is great variability among regions with respect to the number of applications for 
exception points to Share 15 (i.e. requests for points to increase MELD scores for patients to better 
account for the urgency in which they need to be transplanted), which resulted mainly from a lack 
of standardization and oversight.[41] The proportion of DSAs where at least 90% of all liver 
transplants were done on candidates with MELD ≥15 increased significantly.[40] Exception point 
applications did not differ by center competition for organs in the DSA. More than half of all 
applications were approved (64.5%) and candidates were transplanted with a deceased donor organ 
even when an astonishing 80.2% of these patients had a MELD score of less than 15. [41] Given 
the fact that MELD scores 15-17 represent a transition point where scores less than MELD 15 have 
a lower survival benefit, it is surprising that such a high proportion of applications were accepted 
for MELD exception points. This example clearly shows the influence that individual physicians 
have regarding the transplantation process for candidates. Certain physicians or transplantation 
centers might be more inclined to apply for exception points and there could be a selection bias 
for candidates for which physicians are willing to submit these applications.  
Along the same lines as Share 15, another policy change came into effect in 2013. Share 
35 is aimed at increasing transplantations in liver transplant candidates with MELD scores higher 
 17 
than ≥35 which identified very ill candidates with ESLD whose survival benefit of transplantation 
is much higher than that of remaining on the waitlist.[27, 42] Share 35 is successful and is 
associated with more transplants and lower waitlist mortality, without having much effect on the 
early outcomes after transplantation surgery.[40, 42]  
Despite policy updates and creation of a prognostic tool to treat all patients with ESLD 
equally, differences in outcomes exist. Blacks have worse graft and patient survival after liver 
transplantation in comparison to whites.[43-47] Whites have an overall advantage over blacks but 
there is no advantage over Hispanics.[46] Survival rates decrease as recipients further away from 
the date of transplant. At 10 years post transplantation, survival rates were highest in those whom 
were transplanted as children (overall survival is 77% within one year of transplantation, 79% 
survival 1-5 years post transplantation, and 81% survival 6-11 years after transplantation).[43] One 
year graft survival was highest in ages 1-50 (90%), and lowest in children under the age of one 
(83%) and in older adults over the age of 65(81%). [43]  
Since the prevalence of depression is high among candidates while they are still on the 
waitlist (60%), the treatment of depression after liver transplantation was shown to be a better 
predictor of long-term mortality than MELD score, HCV status and donor age.[48] After 
transplantation, the prevalence of depression among patients is curbed but not eliminated 
(prevalence rate 30-40%).[49, 50] A study by Rogal et al showed that there was a difference in ten 
year overall survival between patients that were treated and not treated for depression after 
transplantation. Patients that were treated for depression after surgery had a slightly lower overall 
survival percentage compared with non-depressed recipients (52% versus 56%, respectively). 
Survival in those whom were inadequately or not given treatment for depression was found to be 
32% at ten years post transplantation.[48]  
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Living donors had bad outcomes as a result of biliary, re-hospitalizations due to initial 
transplant and donor suicides within the first year post transplantation.[20, 21] Based on the results 
from the aforementioned study, intervention could be focused on the prevention of suicides in 
living donors through advocacy for increased monitoring and screening prior to and post organ 
donation. Finally, there is large variability in graft outcomes and the location of where the 
transplantation was performed and this has been determined to be an independent predictor of graft 
loss.[51] Variability exists in the way that centers manage complications after surgery; 
complications can be lessened by carefully evaluating donors prior to transplantation in order to 
make sure that they are healthy enough to tolerate such a demanding surgery (i.e. evaluating donor 
BMI, blood pressure, age among other factors). In addition, elimination of complications can also 
be accomplished through skillful surgical technique and attentive follow-up care.[52, 53]  
 
 19 
3.0  KIDNEY TRANSPLANTATION: HISTORICAL PERSPECTIVE AND 
CURRENT STATUS 
Since the establishment of the OPTN and UNOS, like in liver transplantation, there have 
been many allocation systems tried in renal transplantation to increase equality and utility. The 
renal allocation system was first based on HLA matching which was aimed at increasing long term 
graft survival [54] and then it switched to a system based on calculated panel reactive antibodies 
(CPRA). In December 2014, a new allocation system was implemented based on the Kidney Donor 
Profile Index (KDPI) which is derived from data from donors in the previous 12 months, making 
the system incredibly up to date and better able to predict matching between recipients and donors.   
The formerly mentioned HLA based system awarded points based on number of matches 
in the HLA-A, HLA-B, and HLA-DR loci. The system was flawed due to natural variation in HLA 
genotypes between different racial groups.[19] Blacks were poorly served by this system due to 
the natural heterogeneity at these loci, in this population.[12, 19, 54] As was discussed earlier, 
blood group ABO matching continued to create disparities. Graft survival was higher in exact 
ABO matches and worse in compatible matches (type-O as the universal donor for A, B, AB, O). 
In this system, AB (the universal recipient) had the shortest wait time on the transplant list and 
donor type AB organs were discarded at a higher rate than any others. Since the largest proportion 
of donors were and are currently in the type-O blood group, in the HLA-based system type-O 
organs were being offered to compatible recipients, rather than solely to type-O recipients. As a 
result, type-O candidates had longer waiting times and had lower rates of transplantation.[55, 56] 
Allocation policies in renal transplantation then increased use of predictive tools that 
intended to calculate the most appropriate organs for recipients, through matching, by taking into 
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account the recipient’s own biological and epidemiologic characteristics. In order to better estimate 
the proportion of deceased organ donors that would cross match, the calculated panel-reactive 
antibody measure (CPRA) was created. CPRA took into account the HLA frequencies and 
characteristics of the entire donor pool that had been entered into the OPTN registry and was used 
to predict matching between transplant candidates and potential donors.[12, 57] The higher the 
percentage, the more unsuitable organs there are in the donor pool for that individual because the 
recipients antibodies reacted to the antigens of a potential donor, much like they would if the organ 
would be transplanted into that candidate.[57] Using this measure, priority was first assigned to 
recipients receiving multiple organs, secondly priority was given to recipients of cadaveric kidneys 
where there was zero antigen mismatch with the donor, and thirdly, priority was given to ABO 
compatible recipients and the six HLA A, B, DR antigens.[12] Next, all candidate were ranked by 
their CPRA percentage much like the MELD score that was previously discussed, and organs were 
first distributed locally, regionally, and lastly, nationally. Organs were first offered to CPRA ≥80% 
at the local, regional, and national level before they were offered to CPRA 20-79% in this same 
geographic sequence because the higher the CPRA the harder it is to find suitable organs for these 
candidates. If they matched to a particular donor, they were given priority.[12] In order to help 
rank patients within each level of CPRA, candidates were given points. Those who have waited 
the longest were assigned one point and the rest were given fractions of points relative to that 
individual who had waited the longest.[12] 
In order to improve the aforementioned disparities in transplantation rates that had been 
created by this system, attention was focused on prioritizing candidates based on the amount of 
net lifetime benefit that they would receive from the graft.[58] HLA-A and HLA-B matching were 
eliminated because they did not show significantly greater benefit to recipients. This allowed for 
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many more recipients to be matched to potential donors due to the fact that they were being 
matched only at the HLA-DR locus. Matching at this locus proved to be essential for graft 
survival.[59] In addition, elimination of compatible matching between blood groups increased 
transplantation rates in type-O candidates. These major revisions of the allocation policy were 
responsible for a sharp increase in transplantation rates for minorities and decreases in disparities 
based on race and blood group.[12, 55, 59, 60] 
Despite successful policy changes, limitations to the HLA based system existed. The 
system was not able to differentiate the ability of candidates to survive on the waitlist, and it did 
not match donor and recipient characteristics to optimize survival after transplantation. Organs 
from younger donors were being transplanted into older individuals even when these older 
individuals would not get the maximum benefit from the grafts due to their older age. Many were 
dying of other comorbidities with functioning transplanted grafts.[12] Furthermore, HLA 
matching was creating differences in transplantation rates between whites and blacks because it 
did not account for the extensive HLA variation in blacks where extremely rare HLA genotypes 
exist. Caucasians make up the majority of the donor pool thus HLA matching systems naturally 
favor white recipients.[61] In addition, minorities make up the majority of the type-O blood group 
and since compatible matching allowed for type-O organs to be distributed to blood group 
compatible individuals, this caused a shift in organ distribution away from the blood type-O 
group.[39, 61] The cumulative incidence of graft failure was higher among blacks and Hispanics 
than whites. They were more likely to develop acute rejection despite modern 
immunosuppression.[26, 45, 62-65] Furthermore, black race was associated with a higher risk of 
biopsy proven acute rejection at one year post transplant.[63, 65] In a study by Rhee et al, rejection 
rates across all age groups were studied, and it was found that rejection rates were significantly 
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higher in blacks older than 40 but rates for blacks 18-40 were similar to those of whites. They also 
found that Hispanics experienced lower rejection rates than whites.[62, 66] Graft failure was found 
to be highest in recipients who live in poorer areas. This highlights a possible disparity in access 
to healthcare, socioeconomic factors that may play a role in follow-up maintenance and decreased 
monitoring which lead to higher rates of rejection.[44, 63, 67-69] 
In December 2014, UNOS implemented a system based on Kidney Donor Profile Index 
(KDPI) which is a numerical measure based on the Kidney Donor Risk Index (KDRI). The KDRI 
takes into account the relative risk of kidney failure after transplantation in an adult recipient from 
a particular deceased donor based on average donor characteristics.[18] KDPI takes into account 
10 donor factors and summarizes the potential risk of graft failure after kidney transplantation. The 
KDPI ranges from 0% to 100% and the lower the KDPI value, the higher the expected longevity 
is after transplantation therapy and vice versa. The new kidney allocation system (KAS) was 
developed to address the issue of inadequate longevity matching and variability in transplantation 
rates for candidates with high CPRAs. In the new system, all adult kidney candidates receive an 
Expected Post Transplant Survival (EPTS) score which is based on four medical factors: age, time 
on dialysis, current diabetes status, and whether the candidate had a previous solid organ 
transplant. Lower scores are associated with more benefit from longevity kidneys. This would 
likely be a score given to younger candidates. Again, KDPI scores are assigned to donors and 
EPTS scores to recipients in order to achieve better longevity matching so that grafts from younger 
donors would be transplanted in age-matched recipients rather than patients that do not have a high 
predicted longevity. Candidates with CPRA scores greater than 98% are given increased priority 
in the region and nationally. Total dialysis time even prior to wait listing will be taken into account 
for all recipients. This prioritizes patients that have been on dialysis for a long period of time and 
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may impact older recipients by decreasing their survival post transplantation because in addition 
to being on dialysis for the duration of the waiting time, these candidates would be given grafts 
from age-matched donors that would not perform as well as grafts with low KDPI scores. 
Nevertheless, this would decrease unrealized life years from younger grafts being transplanted into 
older candidates. Simulation modeling has predicted that the new KAS will result in over 9,000 
additional life years achieved annually from the current pool of deceased donor kidneys.[70] 
Furthermore, the new system will attempt to address the geographic variation in access to 
transplantation by high CPRA candidates. More organs are expected to be offered at the regional 
and national level. 
Three monitoring reports have been issued by OPTN HRSA databases since the 
implementation of the new Kidney Allocation System (KAS).[71] Three main differences have 
been observed since the implementation of KAS relative to previous rates: there is a seven-fold 
increase in transplantation of candidates with CPRA 99-100%, an increase in non-local transplants 
from previously reported 20% to 35%, and a drop in the number of age mismatched (i.e. longevity 
mismatched where recipients and donors differed by 15 years) transplants from 50% to 41.7%.[71] 
These changes were expected due to the way in which KDPI and EPTS are calculated in order to 
increase longevity matching, the built-in sliding CPRA scale and the broader sharing of organs for 
highly sensitized patients. A high number of candidates with CPRA 99-100% were expected to be 
transplanted initially creating a spike in the number of transplants in this cohort. Many of these 
candidates have been on the waitlist for quite some time and their rates of transplantation will 
decrease due to regional and national priority for CPRA 99-100% patients. In addition to these 
trends, there was an observed increase in transplants in age groups 18-49 and decreases in 
transplants among persons aged 50 and older as well as a decrease in transplantation from 5% to 
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2.2% in pediatric candidates. Likewise, the number of waitlist registrations has also decreased 
slightly in the weeks prior to KAS implementation; the number of registrations in the KAS period 
was 2802.9 compared to the average registration of 3119.7, a drop of 3% from the immediate pre-
KAS period.   
The second and third reports issued by OPTN HRSA in February and March 2015, 
respectively, mirrored the same three trends regarding high rates of transplantation of candidates 
with CPRA 99-100%, decreases in the number of non-local transplants and decreases in age-
mismatched transplants. Significantly fewer zero-mismatch transplants (about 5%) have been 
performed in the first month post-KAS since prior to KAS (about 8%).[72, 73] The same decrease 
in pediatric candidates was observed and it can somewhat be explained by the elevated 
prioritization for very high CPRA patients after KAS implementation. The distribution of 
transplants by candidate age has continued the shift away from candidates over the age of 50 
towards candidates aged 18-49. In addition to these known trends, the proportion of blacks 
undergoing transplantation has increased significantly; they represent 39% of all transplant 
recipients post-KAS implementation.[72, 73] It is possible that this is the result of KAS awarding 
points to time spent on dialysis prior to listing since the waitlist time is known to be higher in this 
group.[12, 19, 61, 74-76]  
Since it is known that transplant rates vary by OPTN region but are relatively fair at the 
level of OPO,  these data warrant a look at the level of DSA and OPO in order to determine if real 
changes in transplantation are present and if known disparities in access to waitlist, transplantation 
of ABO blood groups and differences in outcomes persist in the new KDPI based system.[61]  
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4.0  UNDERLYING DISPARITIES IN LIVER TRANSPLANTATION 
Liver and kidney transplantation rates are impacted greatly by epidemiologic factors that 
cause previously mentioned disparities throughout the entire transplant process. Liver 
transplantation is impacted by age, race, gender, and varying geographic factors. In the liver, the 
MELD based allocation system changes in favor of wait time are impacting older candidates 
negatively.[11, 19, 51] Older individuals are remaining on the waitlists longer due to longevity 
matching that was previously discussed which leads to lower survival rates after transplantation 
due to age-related comorbidities.[77] The race disparity is less pronounced in the MELD system 
as opposed to the pre-MELD era.[24, 34, 77] Whites are typically older and have a higher 
socioeconomic status than blacks and Hispanics at the time of listing, yet their MELD scores are 
lower at transplantation.[46] Blacks and Hispanics are more likely to be insured by the government 
which impacts their likelihood for evaluation and wait-listing for transplantation.[38, 44, 46, 51]  
Access to wait-listing is disproportionately lower in blacks and after wait-listing, their median 
MELD scores are higher than their white counterparts. This suggests that blacks are sicker upon 
listing.[23, 24, 38, 77] HLA matching continues to be an important factor in hindrance to 
transplantation in minorities.[39, 61] There is extensive variation in HLA genotypes in blacks and 
since the majority of the donor pool is made up of whites, matching tends to favor white 
recipients.[61] There are discrepancies in the literature regarding death while on the waitlist for 
blacks. Studies have shown that blacks are more likely to die while on the waitlist which likely 
corresponds to a sicker population being listed, as described by higher MELD scores upon listing, 
lower access to healthcare for ESLD management, and likely confounding by geographic area of 
study.[22, 23, 38, 46] In contrast, Mathur et al reported that blacks had a 37% lower mortality rate 
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than whites while active on the waitlist and that removal from the waitlist did not differ by race.[24]  
It is evidenced by these discrepancies in the literature that geographic variation is a large 
confounder of transplantation rates.[24, 44, 52, 66, 74, 78, 79] Equal rates of transplantation have 
been observed between the larger OPTN regions but differences in the population make up of 
regions will produce differences within regions because minorities are not equally distributed 
among the 11 OPTN regions.[24] When relative transplant rates were compared between blacks 
and whites registered in the same quadrant of the country (grouped contiguous OPTN regions: 
northeast, southeast, northwest, and southwest), blacks had a significantly lower adjusted 
transplant rate versus whites.[23] Similarly, blacks and whites in the same OPTN region had 
differing rates of transplantation but at the level of DSA, the differences disappeared.[23, 24] 
Again, no statistically significant differences were found among the 11 OPTN regions.[23, 24, 38, 
52] Once waitlisted, blacks have the same likelihood of undergoing transplantation as whites.[24, 
34, 38] 
Much like in blacks, race disparities exist in the Hispanic population as well. Hispanics 
have overall lower rates of transplantation and wait-listing despite high rates of referral for 
evaluation for transplantation than whites.[39, 44, 51] This population has high rates of co-
morbidities such as diabetes, hypertension and obesity which leads to high rates of ESLD in this 
population.[46, 51] Hispanics make up the highest proportion of candidates with blood type-O 
which continues to be a limitation to transplantation due to the fact that type-O organs are 
disproportionately given to compatible recipients, thus creating longer waitlists and wait-times for 
type-O candidates.[39] Hispanics are overrepresented at low and medium performing 
transplantation centers and their waitlist time tends to be long because tend to transplant patients 
with higher MELD scores.[51] Populations that are more concentrated in certain parts of the 
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country end up in similar performing centers and are subject to the waitlist disparities at that given 
location.[24, 51] In addition to black and Hispanics, Native Americans had the lowest rates of 
wait-listing prior to and after the introduction of the MELD system whereas the disparities in 
transplantation rates for Asians decreased with the introduction of MELD scores.[26]  
Women face a large disparity in access to transplantation, despite being listed three times 
as often as males.[26, 77] This disparity existed even when women and men were given the same 
MELD score at listing in the same center. Since there is greater benefit of transplantation in MELD 
≥15, women at these high MELD scores are especially vulnerable to becoming too sick to 
transplant or dying while still on the waitlist. This disparity was measured to be 20% in MELD 
scores 20-29 and it was 12% in MELD scores 30-40. In lower MELD scores, the transplantation 
rates are equal.[26] It is possible that MELD scoring could be a poor predictor of disease severity 
in women because it is based, in part, on serum creatinine levels. Women are naturally smaller and 
have less muscle mass which could account for lower levels or creatinine.[26, 80] Creatinine levels 
do not account for all of the disparity in transplantation rates of women because these disparities 
existed prior to the adoption of the MELD score as a prognostic tool. Before MELD scoring was 
the used as the main measure, the difference in transplantation rates between women and men was 
more than 14% lower, but still existent.[26] Given the fact that women have a 9% lower removal 
rate than men from the waitlist due to factors other than transplantation, it is possible that they are 
disproportionately surviving on the waitlists.[26] It is possible that the assigned, calculated MELD 
score could be overestimating the severity of disease in women if they have a higher chance of 
survival on the waitlists. 
Geography not only affects disparities faced by women, but also it affects race, socio-
economic status, and age related disparities that were previously mentioned.[34] Local 
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environments of the transplant centers play a big part in transplant rates. This is especially 
important in minorities because if one race or group of people is more highly concentrated within 
a region and within the borders of a particular OPO, this can lead to higher rates of transplantation 
in these individuals.[61, 81] This accounts for the great variation in candidates per deceased donors 
among the 63 DSAs in the US and it demonstrates why the waitlist removal rates vary greatly.[44, 
81] Transplant recipients at high-volume centers had lower MELD scores and recipients at high-
volume centers also experienced shorter waiting times.[34] High performing centers tended to use 
expanded criteria donor (ECD) organs that carried a higher risk of graft failure due to donor 
specific characteristics such as obesity, diabetes, and hypertension among other factors. In other 
words, the donors might have been on the path to declining liver function themselves. The use of 
extended criteria donor grafts has been reported in centers that are in direct competition with each 
other within the same DSA.[82-84] Centers that use more livers offered at the national level, which 
have been rejected both at the local and regional levels, are likely to have large waitlists and 
patients with high MELD scores, high transplant volumes and be located in competitive DSAs 
where organs are even more scarce due to population demand. Center competition is a direct result 
of the patient volume and center specific motivation to decrease waitlist burdens. Patient outcomes 
are worse in these centers due to use of marginal organs.[83, 84] Competition for organs exists at 
the patient level as well. Candidate listing at more than one DSA is allowed by law and many 
patients list in DSAs with shorter waiting times with transplantations occurring at lower MELD 
scores. The patient demographic that tends to multiple list are individuals that are privately insured, 
college educated, white males with blood type O.[78] For those that can afford to travel, double 
listing greatly increases the likelihood of transplantation.  
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5.0  UNDERLYING DISPARITIES IN KIDNEY TRANSPLANTATION 
The same epidemiologic factors that affect liver transplantation are apparent in kidney 
transplantation. Minorities have a large socioeconomic disadvantage compared to whites, leading 
to lower rates of transplantation, lower rates of wait-listing, decreased availability of living 
donation, and higher discrepancies in HLA matching.[13, 61, 67, 68, 85, 86] It has been reported 
that as neighborhood poverty increases, the likelihood of wait-listing decreases for blacks 
compared to whites. Blacks living in poor neighborhoods (i.e. where more than 20% of the 
population lived below the federal poverty line) had a two-fold lower difference in access to the 
waitlist than their white counterparts.[62, 67] Black ESRD patients are 67% less likely to be placed 
on the deceased donor waitlist.[67, 68, 86]. In this population, failure to complete standard 
requirements for transplantation was higher in blacks and a significant portion of individuals 
reported psychosocial reasoning for failure to complete requirements.[68] A greater portion of 
blacks did not even start the evaluation process.[62, 67, 68] Blacks face greater barriers to wait-
listing than whites.[13, 67, 68, 87-89] Those able to be waitlisted for a transplant, have longer 
waiting times, and tend to be younger and female. Blacks are 38% less likely to receive deceased 
donor transplants due to disparities in HLA matching that have been previously discussed. They 
have a survival advantage on dialysis and they remain on dialysis therapy for longer periods of 
time due to longer wait times to transplantation.[90] Prolonged exposure to dialysis before 
transplantation and black ethnicity are known risk factors for acute rejection and graft loss in 
kidney transplant recipients.[91, 92] This could be an explanation for the higher death rate seen in 
blacks at 60 months post transplantation that was previously mentioned. Graft outcome and overall 
patient survival are shorter for blacks compared to whites.[62, 63]There is greater heterogeneity 
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in this population that complicates matching. However, with the policy to eliminate HLA-B 
matching after the publication by Roberts et al, the disparity in matching decreased by 15% and 
blacks were only 23% less likely to receive transplantation therapy.[59, 60, 93] 
Hispanics experienced similar disparities as blacks in access to kidney transplantation 
therapy.[61, 62, 66, 87, 94] Hispanics make up the largest minority group in the US and are twice 
as likely to develop ESRD at a younger age compared to whites, due to high rates of hypertension 
and diabetes in this population.[66] While this population is equally as likely to be referred for 
transplant therapy, they are waitlisted at a lower rate than whites.[61, 66] This may imply that 
Hispanics are a healthier cohort of people.[61, 66] Graft failure is lower in Hispanics than whites, 
as well.[62] As was the case in the Hispanic population, Native Americans were also more likely 
than whites to be identified as possible candidates for renal transplantation, however they were 
less likely to be listed than whites.[94] 
Geographic differences account for large proportions of the disparities in transplantation 
rates in blacks and Hispanics. Local organ availability is limited by population concentrations, 
Greater demand for transplantation in regions where there is limited organ availability will affect 
access to transplantation.[61] For example, rapidly growing Hispanic populations seem to be 
concentrated in highly populated OPOs in certain regions of the country (i.e. Florida, New York, 
Texas, and California).[61, 66] OPO of listing was found to be the single most important 
contributor of disparities faced by minorities. Nationally, there is greater variability in disparities, 
but at the level of OPO, small differences exist.[61] This national variability will continue to exist 
so long as allocation follows arbitrarily drawn OPTN regional borders.  
A possible way to decrease discrepancy in these minority populations is to increase their 
rates of living donation. Since 1988 living donation had steadily increased in all OPTN regions of 
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the U.S. until 2004. Reasons for such high donations include advances in HLA matching, less 
invasive laparoscopic surgery techniques, greater public awareness of the need for transplant and 
less strict donor eligibility criteria.[76, 95] Research on appropriate donor criteria has shown that 
careful evaluation prior to donation needs to be done. Therefore, this relatively recent decline in 
living donor donations could be the result of shifting donor criteria towards healthier donors with 
lower rates of pre-existing conditions and obesity.[75] Furthermore, increased oversight and low 
performance ratings of centers have had an impact on donation rates. In centers that received low 
performance ratings, there was a decrease of 22 transplants compared to an average decrease of 
eight over study period ranging from 2007-2010.[85] Increases in oversight have led to 
suppression of innovation of surgical technique, decline in use of novel therapies, and increases in 
the use of more conservative policies.[85]  
Currently, women are more likely than men to be living donors [76] and they were less 
likely to want living donation kidney compared with men.[96] Living donation is very low in 
blacks and minorities.[61, 62, 67, 68, 75, 93, 97-100] Studies have found that more individuals in 
this population might be in the early stages of living donor donation that are characterized by 
increasing willingness to learn more about the process. Patients in later stages reported having 
significantly more knowledge of transplantation, increased willingness to talk to family members 
about donation, and fewer concerns about the process.[99] Research has shown that the more trust 
there is in healthcare, the higher the donation rate.[98, 101] Other barriers to donation in blacks 
include financial barriers, as out of pocket costs of donation average to $5,000 due to travel and 
lodging, and lost wages during recovery.[98, 102] The same barriers were observed in Hispanics, 
citing lack of knowledge about the transplant process, family dynamics where certain members 
discourage donation, and financial barriers to donation and fear of being unable to work.[103] 
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Among all living donors, women, Hispanics, and blacks have higher incidence of hospitalizations, 
diagnoses of hypertension and depression, and variable insurance status.[104]  
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6.0  PROPOSED WAYS TO DECREASE AFOREMENTIONED DISPARITIES 
Transplantation therapy has come a long way since its beginnings in the early 20th century; 
however, improvements in policies and education continue to be important ways of decreasing 
disparities between transplant recipient demographics. In liver transplantation, although the 
MELD system is working well, minorities and blacks continue to have difficulty in obtaining 
access to the waitlist. Arbitrarily drawn OPTN regions dictate the flow of organs within large 
metropolises, small towns and rural areas.[16] In one model, re-drawing of the regions to account 
for large populations of possible donor and recipient matches, has increased the intraregional 
number of transplants by more than 130.[105] Redrawing of OPTN borders is an important step 
to improving allocation because the current system is not based on any measureable statistic for 
effectiveness in allocation of organs.[16]  
Another important step in improving liver allocation is the creation of an analogous registry 
for all patients diagnosed with chronic liver disease that can be linked to the Scientific Registry 
for Transplant Recipients (SRTR) in order to facilitate development of allocation policy through 
better estimates of ESLD burden. There is a desperate need for a better defined set of guidelines 
for non-hepatocellular carcinoma patients that can be used in order to better characterize and 
evaluate candidates for transplantation. There is no definitive event that occurs to signify that a 
person has ESLD, therefore a possible step to creating a database is to have healthcare providers 
report incidences of liver related diseases or mentioning transplantation therapy to their patients. 
Possibly adding ESLD or the mentioning transplantation therapy to patients to the list of reported 
diseases could be a way of obtaining the true rate in the population. This on-going reporting would 
not mean that all of the identified patients are eligible for transplantation therapy, but it would give 
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a rough estimate of the disease burden of ESLD, in the United States. Some have argued that a 
minimum MELD score for listing needs to be created.[31, 32] While this would certainly reduce 
transplantation in individuals with low MELD scores, in whom the benefit of transplantation 
therapy is lower than the benefit without the new graft, this change would restrict data gathering 
on waitlist mortality and other factors in this group.[32] These individuals with low MELD scores 
serve as one of the best populations to study in order to determine the burden of ESLD in the 
nationwide population.  
To address the disparity between genders in access to liver transplantation both in the pre-
MELD and the worsening disparity in the MELD era, the MELD score could be adjusted for 
women to account for the naturally low titers of serum creatinine, a large component of MELD 
score calculations.[80]  Furthermore, better treatment of depression in post-transplant populations 
would increase and help to better predict overall survival.[48] Continuous screening of patients for 
depressive symptoms after transplantation therapy is a way of increasing survival by possibly 
improving adherence to antirejection medication regimens and post-operative follow-up. In 
addition, better post-operative depression treatment would likely result in lower rates of inactivity 
and weight gain that are associated with depression, leading to better rehabilitation after 
surgery.[48] 
Alongside these policy changes, public health intervention should focus on vaccinations 
against Hepatitis A and B as well as education efforts to promote healthy lifestyles in order to 
prevent progression to ESLD. Since hepatitis C is the leading cause of ESLD in the U.S., increasing 
education efforts regarding the modes of transmission of the virus is an important step to curbing 
infections. Hepatitis C is spread through blood-to-blood contact and a leading way of transmission 
is through intravenous drug use.[106] The community resources that would be most valuable are: 
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school administrators, parents of those that have died or gotten sick as a result of intravenous drug 
use, nurses and doctors, people working in clinics, sheriffs/local police department and current and 
past intravenous drug users themselves. School administrators are an invaluable part of designating 
drug free areas and making sure that schools have a zero tolerance policy. They could provide 
insight about after-school programs that aim to keep kids off of the streets and providing them 
with anti-drug education so that they do not become the next wave of users. Intervention methods 
relating to intravenous drug use have been studied in adults, however, the same strategies might 
not work well in adolescents and young adults due to differing developmental stages.[106] More 
research is needed in this field. 
As in liver transplantation, policy changes and increasing education efforts through public 
health interventions are possible ways of decreasing observed disparities in kidney transplantation. 
Redrawing of OPTN regions could possibly increase the number of kidney transplants, in the U.S., 
in the same way that was observed after liver allocation remodeling.[105] Likewise, increase living 
donation through policy changes, in particular expanding kidney paired donation (KPD) nationally 
will result in more transplants being done. In practice, KPD is when two pairs of donors and 
recipients are incompatible with their intended recipients. If the donors are both compatible with 
the recipient from the other pair, kidney paired exchange may occur if all parties are willing to 
participate.[18] Currently, the rates of KPD are low largely due to ethical and legal barriers, but 
efforts are still being directed to implementing a National KPD program. In 2005, the New England 
Program for Kidney Exchange (NEPKE) began incorporating donor and recipient pair data into a 
large database that would be able to successfully predict matching pairs, eventually increasing 
matching to three-way paired exchange and even longer chains. The NEPKE computer algorithm 
identifies recipients who are ABO compatible with the donor pool; if an incompatibility is found, 
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this donor is eliminated from the results. Long transplant chains can be built if there is an altruistic 
donor present who is not paired with a recipient. This donor starts a chain by donating an organ to 
a matched pair whose donor will eventually give to another pair and the chain will continue until 
it breaks.[107] Breaks in the chain result from either the recipient or donor wishing to no longer 
participate, or the recipient denying the organ which has been offered. Even though kidney paired 
exchange is an effective way of increasing living donor transplants, it is somewhat unreliable 
because the identified pairs could change their minds regarding surgery and affect many other 
candidates. To minimize possible breaks, the new system for allocation of kidneys has limited 
chains to 20 donor recipient chains.[18] Despite this drawback of relying on patients to make 
clinical decisions, in 2010, UNOS piloted the National KPD program where four coordinating 
centers were charged with enrolling patients into the paired exchange database. The eventual goal 
is to link these databases to the main UNOS database that links all OPOs and transplant centers 
and allow for any transplant center to participate in KDP program.[107]  
In conjunction with wide-spanning policies, increasing knowledge of the transplantation 
process through education efforts from community wide interventions is a method for not only 
increasing living donation rates in blacks and minorities, but also decreasing barriers to wait-listing 
by possibly making these populations more likely to initiate conversations regarding 
transplantation with their physicians. This intervention could potentially introduce increases in 
available organs for transplantation and decrease the exponentially growing waitlist. Together with 
these community wide interventions, public health intervention should focus on increasing 
education on the leading causes of ESRD: hypertension, diabetes, and obesity. Promotion of 
physical activity and healthy diets are key. Walking paths, bike lanes and farmers markets could 
be incorporated into communities with high rates of obesity in order to increase physical activity 
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in these populations. Furthermore, healthcare providers can initiate more conversations with 
patients regarding these pre-cursors to ESRD, or, provide information to family members so that 
the conversations regarding healthy living can be initiated at home. 
The solutions for observed disparities in both liver and kidney transplantation are not 
obvious. Effective policy changes in conjunction with educational efforts relating to greater public 
health have the potential to ameliorate observed health differences between populations and, in 
some cases, eliminate the progression to ESLD or ESRD altogether. For those patients who 
progress to the point of needing transplantation therapy, these same policy changes have the 
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